Liofilchem® Cefiderocol FDC Antimicrobial Susceptibility Discs, 30 µg

Liofilchem® Cefiderocol Discs (30 µg) are specialized antimicrobial susceptibility testing (AST) discs designed for in vitro use with the Kirby-Bauer disk diffusion method on Mueller-Hinton agar. Each disc is impregnated with 30 micrograms of Cefiderocol, a novel siderophore cephalosporin antibiotic engineered for potent activity against multidrug-resistant (MDR) Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia. These discs comply with ISO 9001 and ISO 13485 manufacturing standards and provide highly reproducible results in clinical and research settings.

Key Features

• Innovative antibiotic class: Cefiderocol combines cephalosporin activity with iron-chelating siderophore properties for enhanced uptake in Gram-negative bacteria.
• High precision content: Each disc contains 30 µg of Cefiderocol for standardized testing.
• Compliant with CLSI and EUCAST: Meets international AST guidelines for accuracy and comparability.
• Sterile and shelf-stable: Supplied in sealed cartridges or canisters to preserve potency and prevent contamination.
• Color-coded labeling: Allows easy identification of antibiotic type and concentration.

Applications and Use Cases

1. Clinical Microbiology

Used in advanced diagnostic microbiology laboratories to:

• Detect susceptibility of difficult-to-treat Gram-negative organisms, especially those resistant to carbapenems.
• Assist clinicians in selecting Cefiderocol for treatment of:
  • Bloodstream infections (BSIs)
  • Hospital-acquired pneumonia (HAP)
  • Ventilator-associated pneumonia (VAP)
  • Complicated urinary tract infections (cUTIs)

2. Infectious Disease Surveillance

• Monitor antimicrobial resistance trends in carbapenemase-producing organisms.
• Support national and institutional antimicrobial stewardship programs by guiding targeted therapy.

3. Research and Development

• Evaluate the activity of Cefiderocol in in vitro studies and experimental protocols.
• Investigate resistance mechanisms involving iron-transport systems in Gram-negative bacteria.
• Assess combinatorial therapy with other last-resort antibiotics.

Use Instructions

1. Prepare Mueller-Hinton agar plates using standard procedures.
2. Adjust the inoculum to a 0.5 McFarland turbidity standard.
3. Inoculate the entire surface of the agar plate uniformly.
4. Apply the Cefiderocol disc (30 µg) using sterile forceps or a disc dispenser.
5. Incubate the plate at 35 ± 2 °C for 16–20 hours.
6. Measure the diameter of the inhibition zone in millimeters.
7. Interpret the results based on the most current CLSI or EUCAST breakpoint tables (specific breakpoints are published for Cefiderocol against Enterobacterales, Pseudomonas, and Acinetobacter species).

Storage and Shelf Life

• Storage Temperature: 2–8 °C (Refrigerated)
• Shelf Life: 24–36 months from the date of manufacture when unopened and properly stored.

Liofilchem® Cefiderocol FDC Discs (30 µg) are advanced AST tools designed to address the pressing global challenge of antimicrobial resistance, especially among carbapenem-resistant Gram-negative bacteria. Their accuracy, reliability, and alignment with international testing standards make them ideal for clinical diagnostics, resistance surveillance, and antimicrobial research. These discs support evidence-based treatment decisions and foster the development of targeted therapies in the face of MDR pathogens.